Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
145
resultados
Última actualización
28/06/2025 [08:48:00]
Resultados 100 a 125 de 145
Resumen de: WO2025095553A1
A pharmaceutical composition for preventing or treating dementia diseases, containing, as an active ingredient, an isoquinoline derivative compound or a pharmaceutically acceptable salt thereof, of the present invention, does not induce cytotoxicity and can alleviate learning and memory abnormalities in an animal model of Alzheimer's dementia, and thus is expected to be effectively used in the development of therapeutic agents for dementia diseases.
Resumen de: AU2023367200A1
The present disclosure provides methods for achieving optimal levels of bevemipretide (also known as "(R)-2-amino-N-((S)- 1 -(((S)-5-amino- 1 -(3 -benzyl- 1,2,4-oxadiazol-5- yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5- guanidinopentanamide" or "SBT-272"), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, in brain tissue of subjects suspected of having, suffering from, or at risk for a neurodegenerative disease, such as, but not limited to amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), PD with dementia, dementia with Lewy bodies, Multiple System Atrophy, Huntington's disease, HTT proteinopathy, Frontotemporal Lobar Degeneration (FTLD), a tauopathy, and other disease where TDP-43, Tau protein, and α-synuclein are associated with the disease pathology.
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Resumen de: US2025145695A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2025093735A2
The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal/mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42/Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.
Resumen de: KR20250063452A
본 발명은 상염색체우성 알츠하이머병에서 노화 조절을 통한 아밀로이드 병리 제거에 최적 시기 및 방법을 확인하여 완성된 것으로서, 노화세포 표적 약물을 진행된 알츠하이머병 환자에 투여하여 알츠하이머병을 치료하는 방법 등을 제공하여 노화 조절을 통한 새로운 패러다임의 알츠하이머병의 치료적 접근을 가능하게 하며, 상기 방법의 효과적인 치료시기를 제공함으로써 진행된 알츠하이머병 환자를 대상으로 하는 다각적 치료방법의 하나로 이용될 수 있다.
Resumen de: US2025146000A1
The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
Resumen de: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Resumen de: US2025144159A1
A composition comprising a mixture of DHA and/or EPA in the form of glyceride or ethylester derived from at least one microorganism, such as a microalga, and at least one plant-derived phospholipid, in which the content of DHA and/or EPA in triglyceride form is between 10% and 90% by weight relative to the total weight of the composition, and the content of at least one plant-derived phospholipid, such as phosphatidylcholine, is between 10% and 90% by weight relative to the weight of composition. The method for manufacturing same and to the use thereof, in particular in the treatment of pathologies involving a deficiency of DHA and/or EPA, such as age-related macular degeneration or Alzheimer's disease.
Resumen de: US2025144135A1
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Resumen de: EP4549585A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Resumen de: EP4549579A1
A composition of the present disclosure contains edaravone and is used for causing a change in expression level of a gene product in a target. The gene product is a gene product of one or more genes selected from KAZALD1, SBK1, SCN2A, UBE2L6, ALPL, NTM, PTTG1, ITGB4, HAUS4, DCTD, MT2A, ASF1B, FCSK, MAST1 and FAIM2. The composition is also suitably used as a pharmaceutical. The composition is also suitably used for treating or preventing a neurodegenerative disease. The neurodegenerative disease is suitably amyotrophic lateral sclerosis (ALS). The present disclosure also provides a method for evaluating responsiveness of edaravone based on an expression level of the gene product or a change in the expression level.
Resumen de: CN119909151A
The invention belongs to the field of traditional Chinese medicines, discloses a novel application of a gastrodia elata dizziness-relieving preparation, and particularly relates to an application of the gastrodia elata dizziness-relieving preparation in medicines for preventing and treating Parkinson's disease and motor complications thereof. The gastrodia elata dizziness relieving preparation is prepared from 12 raw medicinal materials including gastrodia elata, uncaria, rhizoma alismatis, pinellia ternate, bighead atractylodes rhizome, poria cocos, radix paeoniae alba, caulis bambusae in taeniam, ligusticum wallichii, liquorice, pericarpium citri reticulatae and ginger. Modern pharmacodynamic test research shows that the gastrodia elata dizziness relieving preparation can regulate expression of alpha-synuclein, LC3B and Beclin1 of a Parkinson's disease model rat group, and has a neuroprotective effect on the model rats; the gastrodia elata Jiangning granules have obvious effects of improving behavioristics of Parkinson's disease model mice, and have good prevention and treatment effects on motion fluctuation and dyskinesia of Parkinson's disease and complications of Parkinson's disease.
Resumen de: NZ776663A
A method of determining the epigenetic chromosome interactions which are relevant to a companion diagnostic. In particular, the present invention relates to an in vitro method for determining predisposition to amyotrophic lateral sclerosis in a person, wherein the method comprises detecting the presence or absence of epigenetic chromosome interaction markers.
Resumen de: NZ746628A
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I) : wherein each symbol is as defined in the specification, or a salt thereof.
Resumen de: CN119909043A
The invention discloses a multi-system drug release system for Parkinson's disease treatment, which is a capsule prepared from the following drug release systems and auxiliary materials in percentage by weight: 58.0 to 64.1 percent of an entacapone drug release system, 28.5 to 31.5 percent of a levodopa drug release system, 7.6 to 8.4 percent of a carbidopa drug release system and 0.5 to 1.5 percent of talcum powder, the drug-loaded pellet of the entacapone drug release system comprises a first pellet core, an isolation layer and an enteric layer which are sequentially arranged from inside to outside, and the drug-loaded pellet of the levodopa drug release system comprises a second pellet core and a first modification layer which are sequentially arranged from inside to outside, the drug-loaded pellet of the carbidopa drug release system comprises a third pellet core and a second modification layer which are sequentially arranged from inside to outside. The multi-system drug release system can realize independent and long-term slow release of three different active components without mutual interference. According to the method, a multi-system drug release system can be prepared with high loading capacity, and the problem of large dosage of drugs is effectively solved.
Resumen de: CN119909099A
The invention provides application of ackermania kwangsiensis in preparation of a medicine for preventing and/or treating Alzheimer's disease, and belongs to the technical field of biological medicines. The invention provides application of ackermania kwangsiensis or a probiotic agent containing the ackermania kwangsiensis in preparation of a medicine for preventing and/or treating the Alzheimer's disease. According to the present invention, the pharmacological experiment is performed by using the D-galactose induced mouse cognitive impairment model as the experiment, and the result shows that the ackermania kwangsiensis not only can effectively improve the autonomous exploration ability and the learning cognitive ability, but also can improve the expression level of the BDNF in the hippocampus, such that the ackermania kwangsiensis can be used for developing or preparing the Alzheimer's disease treatment drug.
Resumen de: CN119912323A
The invention relates to a method for extracting sesquiterpenoids from stems and leaves of rhizoma arisaematis and application of the sesquiterpenoids, the sesquiterpenoids G and I can be effectively extracted from the stems and leaves of rhizoma arisaematis, and the problem of preparing medicines for treating Alzheimer's Disement.The preparation method comprises the steps that the dried stems and leaves of rhizoma arisaematis are taken to be smashed, heated and refluxed, filtered, concentrated under reduced pressure and dissolved with water, and a mixture is obtained; sequentially and respectively extracting with petroleum ether, ethyl acetate and n-butyl alcohol, concentrating and drying; the method is easy to operate, scientific and reasonable, the sesquiterpenoids G and I can be effectively extracted from the stems and leaves of the rhizoma arisaematis, the sesquiterpenoids G and I can remarkably improve PC-12 cell damage induced by Abeta25-35, new application of active ingredients in the stems and leaves of the rhizoma arisaematis is developed, and the sesquiterpenoids G and I are obtained. The commercial and use values of the rhizoma arisaematis are improved, meanwhile, a new way of the medicine for treating the Alzheimer's disease is developed, and the economic and social benefits are huge.
Resumen de: CN119912357A
The invention relates to the technical field of medicinal chemistry and biological medicine, in particular to an alpha-p-aminobenzal-5, 6-dimethoxy-1-indanone derivative as well as a preparation method and application of the alpha-p-aminobenzal-5, 6-dimethoxy-1-indanone derivative. The alpha-p-aminobenzylidene-5, 6-dimethoxy-1-indanone derivative is characterized in that the alpha-p-aminobenzylidene-5, 6-dimethoxy-1-indanone derivative has a structural general formula as shown in a general formula I in the specification. The alpha-p-aminobenzylidene-5, 6-dimethoxy-1-indanone derivative prepared by the invention can be used for preparing a medicine for preventing or treating the Alzheimer's disease, and has an important medicinal value and a wide application prospect in research and development of the medicine for treating the Alzheimer's disease.
Resumen de: CN119909093A
The invention belongs to the field of biological medicines, and particularly relates to a composition of chondroitin sulfate oligosaccharide and application of the composition in preparation of a Parkinson's disease treatment medicine. The chondroitin sulfate oligosaccharide is chondroitin sulfate octasaccharide from which a 6-site sulfuric acid group is removed and a 4-site sulfuric acid group is specifically retained; the chondroitin sulfate oligosaccharide oral preparation is a composition containing sodium N-(8-2-hydroxybenzoyl-amino) caprylate (SNAC) and chondroitin sulfate octasaccharide retaining a 4-position sulfuric acid group. The N-(8-2-hydroxybenzoyl-amino) sodium caprylate can effectively promote oral absorption of chondroitin sulfate, and can be used as an oral absorption enhancer; the chondroitin sulfate oligosaccharide has neuroprotective activity and can be used for treating Parkinson's disease.
Resumen de: CN119912402A
The invention provides an FTO (fluorine-doped tin oxide) inhibitor as well as a preparation method and application thereof, and particularly discloses 2-(substituted benzene miscellaneous group) aromatic formic acid as shown in the following general formula (I), derivative compounds of the 2-(substituted benzene miscellaneous group) aromatic formic acid and pharmaceutically acceptable salts, hydrates or solvates of the 2-(substituted benzene miscellaneous group) aromatic formic acid, which can be used as an FTO target inhibitor for treating diseases related to the FTO target. The compound can be used for treating human myelodysplastic syndrome, such as leukemia, lymphoma, myelodysplastic syndrome, obesity, metablic syndrome (MS), type II diabetes (Type 2 diabetes, T2D), Alzheimer's disease, breast cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, small cell lung cancer, human bone marrow rhabdomyoma, pancreatic cancer, malignant glioblast brain tumor and the like. # imgabs0 #
Resumen de: CN119912417A
The invention discloses a method for extracting rhizoma arisaematis terpenes E and F from rhizoma arisaematis stems and leaves and application of the rhizoma arisaematis terpenes E and F, epimers E and F can be effectively separated from the rhizoma arisaematis stems and leaves, and the problem of medication for treating the Alzheimer's disease is solved. The invention discloses a rhizoma arisaematis epimer compound E and F. The rhizoma arisaematis epimer compound E and F are prepared by the following steps: extracting rhizoma arisaematis stems and leaves with n-butyl alcohol, respectively concentrating and drying, taking the concentrated and dried ethyl acetate part to be loaded on a column, eluting, purifying, eluting, collecting fractions within retention time, concentrating and drying, the preparation method is easy to operate, scientific and reasonable, the epimer compounds E and F can be effectively extracted from the rhizoma arisaematis stems and leaves, and the compounds can obviously improve Abeta25-35 induced PC-12 cell injury and have a good application prospect. The rhizoma arisaematis stem leaves are effectively used for preparing the medicine for treating the Alzheimer's disease, the medicinal and commercial values of the rhizoma arisaematis stem leaves are developed, the utilization rate is increased, medicine sources are increased, and the economic and social benefits are remarkable.
Resumen de: WO2025087971A1
The invention relates to the treatment of Alzheimer's disease in a human patient, said treatment comprising administration of an anti-Aβ antibody component and co-administration of edaravone, the anti-Aβ antibody component being selected from anti-Aβ antibody, an Aβ- binding fragment of an Aβ antibody, a vectorised anti-Aβ antibody and a vectorised Aβ- binding fragment of an Aβ antibody.
Resumen de: AU2023406056A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Nº publicación: AU2023347329A1 01/05/2025
Solicitante:
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES, INC
Resumen de: AU2023347329A1
This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter-2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of the compounds.
BOPI
Sede Electrónica
